Evidence map›Paper›PMID 29934409›Full record

ArticleThe oncologist2019

Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer.

Marie Lange, Natacha Heutte, Sabine Noal, Olivier Rigal, Jean-Emmanuel Kurtz, Christelle Lévy, Djelila Allouache, Chantal Rieux, Johan Lefel, Bénédicte Clarisse and 9 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Long-Term Cognitive Dysfunction in Cancer Survivors.Frontiers in molecular biosciences · 2021
    Review
  16. Co-occurrence of decrements in physical and cognitive function is common in older oncology patients receiving chemotherapy.European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2020
    Article
  17. Beta-Blockers and Cancer: Where Are We?Pharmaceuticals (Basel, Switzerland) · 2020
    Review
  18. Review
  19. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.Annals of oncology : official journal of the European Society for Medical Oncology · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 1 country.

Marie LangeINSERM, U1086, ANTICIPE, Caen, France.
Natacha HeutteClinical Research Department, Caen, France.
Sabine NoalBreast Committee Department, Centre François Baclesse, Caen, France.
Olivier RigalCancer & Cognition, Platform, Ligue Contre le Cancer, CHU de Caen, Caen, France.
Jean-Emmanuel KurtzOncology-Hematology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Christelle LévyBreast Committee Department, Centre François Baclesse, Caen, France.
Djelila AllouacheBreast Committee Department, Centre François Baclesse, Caen, France.
Chantal RieuxClinical Research Department, Caen, France.
Johan LefelDepartments of Care Support, Centre Henri-Becquerel, Rouen, France.
Bénédicte ClarisseClinical Research Department, Caen, France.
Alexandra LeconteClinical Research Department, Caen, France.
Corinne VeyretMedical Oncology, Centre Henri-Becquerel, Rouen, France.
Philippe BarthélémyOncology-Hematology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Nadine LongatoOncology-Hematology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Laure TronINSERM, U1086, ANTICIPE, Caen, France.
Hélène CastelINSERM U982, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Rouen University, Mont-Saint-Aignan, France.
Francis EustacheNormandie University, UNICAEN, PSL Research University, EPHE, INSERM, U1077, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine Department, Caen, France.
Bénédicte GiffardCancer & Cognition, Platform, Ligue Contre le Cancer, CHU de Caen, Caen, France.
Florence JolyINSERM, U1086, ANTICIPE, Caen, France f.joly@baclesse.fr.
Centre François Baclesse · FRHôpitaux Universitaires de Strasbourg · FRUniversité de Caen Normandie · FRCentre Hospitalier Universitaire de Caen · FRInserm · FRCentre Virchow-Villermé · FRUniversité Paris Sciences et Lettres · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGroup-based trajectory modeling is particularly important to identify subgroups of patients with pathological cognitive changes after cancer treatment. To date, only one study has explored cognitive trajectories in older patients with cancer. The present article describes objective cognitive changes before to after adjuvant treatment in older adults with early-stage breast cancer (EBC) after adjuvant treatment compared with healthy controls. PATIENTS AND

methodsParticipants were patients ≥65 years of age with newly diagnosed EBC and healthy controls (age-, sex-, and education-matched). The pretreatment assessment was conducted before adjuvant therapy, and the post-treatment assessment after the end of the first adjuvant treatment. Objective cognitive changes before to after treatment were evaluated based on the Reliable Change Index for cognitive decline accounting for cognitive impairment status.

resultsThe sample consisted of women newly diagnosed with EBC (

conclusionThis study described for the first time objective cognitive changes before to after treatment of older adults with EBC immediately after the end of adjuvant treatment. A longer-term remote follow-up of adjuvant treatment is needed to better understand the cognitive trajectories of older patients with EBC. IMPLICATIONS FOR PRACTICE: After the end of adjuvant treatment, 31% of older adults with early-stage breast cancer without initial objective cognitive impairment developed impairment, and 6% experienced accelerated cognitive decline. Initial cognitive functioning should be included in the balance of benefits and harms of systemic therapy for patients who are likely to be at highest risk for cognitive decline after cancer treatments. Regular cognitive follow-up of patients who had cognitive impairment before cancer treatment should monitor symptoms suggestive of neurodegenerative disease and avert the effect of cognitive disorders on patients' autonomy.

Indexed as

AgedBreast NeoplasmsChemotherapy, AdjuvantCognition DisordersFemaleHumansAgingBreast neoplasmsChemotherapyCognition disordersCognitive changes

Identifiers

PMID29934409
PMCPMC6324624
OpenAlexW2809355859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.